These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 28673045

  • 21. A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus.
    Burggraaf B, Pouw NMC, Arroyo SF, van Vark-van der Zee LC, van de Geijn GM, Birnie E, Huisbrink J, van der Zwan EM, Mulder MT, Rensen PCN, de Herder WW, Cabezas MC.
    Diabetes Obes Metab; 2020 May; 22(5):807-816. PubMed ID: 31912632
    [Abstract] [Full Text] [Related]

  • 22. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
    Bonnefond A, Yengo L, Le May C, Fumeron F, Marre M, Balkau B, Charpentier G, Franc S, Froguel P, Cariou B, DESIR study group.
    Diabetologia; 2015 Sep; 58(9):2051-5. PubMed ID: 26049403
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
    Ooi TC, Cousins M, Ooi DS, Steiner G, Uffelman KD, Nakajima K, Simo IE.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
    [Abstract] [Full Text] [Related]

  • 25. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.
    Hooper AJ, Heeks L, Robertson K, Champain D, Hua J, Song S, Parhofer KG, Barrett PH, van Bockxmeer FM, Burnett JR.
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1484-90. PubMed ID: 26323024
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
    Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL.
    JAMA; 2019 Jan 29; 321(4):364-373. PubMed ID: 30694319
    [Abstract] [Full Text] [Related]

  • 28. Predicting proprotein convertase subtilisin kexin type-9 loss of function mutations using plasma PCSK9 concentration.
    Wanneh E, Luna G, Dufour R, Baass A.
    J Clin Lipidol; 2017 Jan 29; 11(1):55-60. PubMed ID: 28391911
    [Abstract] [Full Text] [Related]

  • 29. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia.
    Twickler TB, Dallinga-Thie GM, de Valk HW, Schreuder PC, Jansen H, Cabezas MC, Erkelens DW.
    Arterioscler Thromb Vasc Biol; 2000 Nov 29; 20(11):2422-7. PubMed ID: 11073847
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The atherogenic plasma remnant-like particle cholesterol concentration is increased in the fasting and postprandial state in active acromegalic patients.
    Twickler TB, Dallinga-Thie GM, Zelissen PM, Koppeschaar HP, Erkelens DW.
    Clin Endocrinol (Oxf); 2001 Jul 29; 55(1):69-75. PubMed ID: 11453954
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors.
    Krysa JA, Ooi TC, Proctor SD, Vine DF.
    J Nutr; 2017 Apr 29; 147(4):473-481. PubMed ID: 28179493
    [Abstract] [Full Text] [Related]

  • 36. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, Devay RM, Liang H, Rashid S, Linton MF, Fazio S.
    Cardiovasc Res; 2016 May 15; 110(2):268-78. PubMed ID: 26980204
    [Abstract] [Full Text] [Related]

  • 37. Association of Rare Protein-Truncating DNA Variants in APOB or PCSK9 With Low-density Lipoprotein Cholesterol Level and Risk of Coronary Heart Disease.
    Dron JS, Patel AP, Zhang Y, Jurgens SJ, Maamari DJ, Wang M, Boerwinkle E, Morrison AC, de Vries PS, Fornage M, Hou L, Lloyd-Jones DM, Psaty BM, Tracy RP, Bis JC, Vasan RS, Levy D, Heard-Costa N, Rich SS, Guo X, Taylor KD, Gibbs RA, Rotter JI, Willer CJ, Oelsner EC, Moran AE, Peloso GM, Natarajan P, Khera AV.
    JAMA Cardiol; 2023 Mar 01; 8(3):258-267. PubMed ID: 36723951
    [Abstract] [Full Text] [Related]

  • 38. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 39. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.
    Lambert G, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, Laboisse C, Krempf M, Costet P.
    Endocrinology; 2006 Oct 15; 147(10):4985-95. PubMed ID: 16794006
    [Abstract] [Full Text] [Related]

  • 40. Postprandial lipemia associates with liver fat content.
    Matikainen N, Mänttäri S, Westerbacka J, Vehkavaara S, Lundbom N, Yki-Järvinen H, Taskinen MR.
    J Clin Endocrinol Metab; 2007 Aug 15; 92(8):3052-9. PubMed ID: 17488790
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.